These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 26121630)

  • 1. [Impact of Teriparatide on Quality of Life in Osteoporotic Patients].
    Osca Guadalajara M; Guadalajara Olmeda N; Escartín Martínez R
    Rev Esp Salud Publica; 2015 Apr; 89(2):215-25. PubMed ID: 26121630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS).
    Langdahl BL; Ljunggren Ö; Benhamou CL; Marin F; Kapetanos G; Kocjan T; Lespessailles E; Napoli N; Nikolic T; Petto H; Moll T; Lindh E
    Calcif Tissue Int; 2016 Sep; 99(3):259-71. PubMed ID: 27137783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study description and baseline characteristics of the population enrolled in a multinational observational study of extended teriparatide use (ExFOS).
    Ljunggren O; Benhamou CL; Dekker J; Kapetanos G; Kocjan T; Langdahl BL; Napoli N; Petto H; Nikolić T; Lindh E
    Curr Med Res Opin; 2014 Aug; 30(8):1607-16. PubMed ID: 24720366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting.
    Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Langdahl BL; Fahrleitner-Pammer A; Walsh JB; Gibson A; Tynan AJ; Marin F
    Curr Med Res Opin; 2008 Feb; 24(2):377-84. PubMed ID: 18154690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline characteristics of the population enrolled in the Italian Observational Study on Severe Osteoporosis (ISSO).
    Adami S; Maugeri D; Toscano V; Topa G; Carminiti M; Brancati A; Massarotti M; Osella G; Malavolta N; Iolascon G; Cagnoni C; Camozzi V; Corradini C; Nardi A; Migliaccio S; Ulivieri FM; Resmini G; Valle D; Tauchmanovà L; Silvestri S;
    Clin Exp Rheumatol; 2011; 29(3):477-84. PubMed ID: 21640043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS).
    Fahrleitner-Pammer A; Langdahl BL; Marin F; Jakob F; Karras D; Barrett A; Ljunggren Ö; Walsh JB; Rajzbaum G; Barker C; Lems WF
    Osteoporos Int; 2011 Oct; 22(10):2709-19. PubMed ID: 21113576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS).
    Napoli N; Langdahl BL; Ljunggren Ö; Lespessailles E; Kapetanos G; Kocjan T; Nikolic T; Eiken P; Petto H; Moll T; Lindh E; Marin F
    Calcif Tissue Int; 2018 Oct; 103(4):359-371. PubMed ID: 29909449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study.
    Rajzbaum G; Grados F; Evans D; Liu-Leage S; Petto H; Augendre-Ferrante B
    Joint Bone Spine; 2014 Jan; 81(1):69-75. PubMed ID: 23796729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).
    Soen S; Fujiwara S; Takayanagi R; Kajimoto K; Tsujimoto M; Kimura S; Sato M; Krege JH; Enomoto H
    Curr Med Res Opin; 2017 Nov; 33(11):2049-2056. PubMed ID: 28699789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
    Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
    Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study.
    Ljunggren Ö; Barrett A; Stoykov I; Langdahl BL; Lems WF; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Karras D; Marin F
    BMC Musculoskelet Disord; 2013 Aug; 14():251. PubMed ID: 23968239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in health-related quality of life in osteoporosis patients treated with teriparatide.
    Lau AN; Ali SH; Sawka AM; Thabane L; Papaioannou A; Gafni A; Adachi JD
    BMC Musculoskelet Disord; 2008 Nov; 9():151. PubMed ID: 18990249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS).
    Aloumanis K; Kapetanos G; Bartzis N; Drossinos V;
    BMC Musculoskelet Disord; 2015 Jun; 16():136. PubMed ID: 26044820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.
    Soen S; Fujiwara S; Takayanagi R; Sato M; Tsujimoto M; Yamamoto T; Enomoto H; Krege JH
    Curr Med Res Opin; 2015; 31(9):1771-9. PubMed ID: 26189932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of Teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS).
    Walsh JB; Lems WF; Karras D; Langdahl BL; Ljunggren O; Fahrleitner-Pammer A; Barrett A; Rajzbaum G; Jakob F; Marin F
    Calcif Tissue Int; 2012 May; 90(5):373-83. PubMed ID: 22466444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-year results from the EFOS study.
    Karras D; Stoykov I; Lems WF; Langdahl BL; Ljunggren Ö; Barrett A; Walsh JB; Fahrleitner-Pammer A; Rajzbaum G; Jakob F; Marin F
    J Rheumatol; 2012 Mar; 39(3):600-9. PubMed ID: 22247365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced risk of back pain following teriparatide treatment: a meta-analysis.
    Nevitt MC; Chen P; Dore RK; Reginster JY; Kiel DP; Zanchetta JR; Glass EV; Krege JH
    Osteoporos Int; 2006 Feb; 17(2):273-80. PubMed ID: 16142502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Back pain in patients with severe osteoporosis on teriparatide or antiresorptives: a prospective observational study in a multiethnic population.
    Songpatanasilp T; Mumtaz M; Chhabra H; Yu M; Sorsaburu S
    Singapore Med J; 2014 Sep; 55(9):493-501. PubMed ID: 25273935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS).
    Langdahl BL; Rajzbaum G; Jakob F; Karras D; Ljunggren O; Lems WF; Fahrleitner-Pammer A; Walsh JB; Barker C; Kutahov A; Marin F
    Calcif Tissue Int; 2009 Dec; 85(6):484-93. PubMed ID: 19823760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Back pain treatment in post-menopausal osteoporosis with vertebral fractures.
    Ulivieri FM
    Aging Clin Exp Res; 2007 Jun; 19(3 Suppl):21-3. PubMed ID: 18180603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.